Barclays PLC Lowers Holdings in Indivior PLC (NASDAQ:INDV)

Barclays PLC reduced its stake in shares of Indivior PLC (NASDAQ:INDV) by 54.6% in the 3rd quarter, Holdings Channel reports. The fund owned 2,130,902 shares of the company’s stock after selling 2,559,245 shares during the period. Barclays PLC’s holdings in Indivior were worth $20,776,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of INDV. Iron Triangle Partners LP purchased a new stake in shares of Indivior during the 3rd quarter worth about $8,243,000. Krensavage Asset Management LLC acquired a new position in Indivior in the 3rd quarter worth about $6,843,000. Millennium Management LLC boosted its position in Indivior by 48.1% during the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock worth $7,952,000 after purchasing an additional 160,282 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in Indivior in the third quarter valued at approximately $2,632,000. Finally, Clark Estates Inc. NY acquired a new stake in Indivior in the third quarter valued at approximately $2,477,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Price Performance

Shares of NASDAQ INDV opened at $11.57 on Friday. The firm has a 50-day simple moving average of $9.96 and a 200-day simple moving average of $11.91. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -289.25 and a beta of 0.75. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $23.22.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. On average, equities analysts predict that Indivior PLC will post 1.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INDV has been the topic of a number of recent analyst reports. Craig Hallum decreased their target price on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th. Piper Sandler restated an “overweight” rating and set a $16.00 price objective (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.